RESUMEN
Dengue virus (DENV) from the Flaviviridae family causes an epidemic disease that seriously threatens human life. The viral serine protease NS2B-NS3 is a promising target for drug development against DENV and other flaviviruses. We here report the design, synthesis, and in-vitro characterization of potent peptidic inhibitors of DENV protease with a sulfonyl moiety as N-terminal cap, thereby creating sulfonamide-peptide hybrids. The in-vitro target affinities of some synthesized compounds were in the nanomolar range, with the most promising derivative reaching a Ki value of 78 nM against DENV-2 protease. The synthesized compounds did not have relevant off-target activity nor cytotoxicity. The metabolic stability of compounds against rat liver microsomes and pancreatic enzymes was remarkable. In general, the integration of sulfonamide moieties at the N-terminus of peptidic inhibitors proved to be a promising and attractive strategy for further drug development against DENV infections.
Asunto(s)
Virus del Dengue , Dengue , Animales , Humanos , Ratas , Inhibidores de Proteasa Viral/uso terapéutico , Inhibidores de Proteasas/química , Antivirales/química , Péptidos/farmacología , Péptidos/uso terapéutico , Serina Endopeptidasas/metabolismo , Dengue/tratamiento farmacológico , Proteínas no Estructurales ViralesAsunto(s)
Síndrome Post Agudo de COVID-19 , Inhibidores de Proteasa Viral , Humanos , COVID-19/epidemiología , COVID-19/prevención & control , Síndrome Post Agudo de COVID-19/epidemiología , Síndrome Post Agudo de COVID-19/prevención & control , Ritonavir , Inhibidores de Proteasa Viral/uso terapéutico , United States Department of Veterans AffairsRESUMEN
In lab studies, SARS-CoV-2 finds ways to evade key drug. Some of the viral mutations are already found in people.
Asunto(s)
Tratamiento Farmacológico de COVID-19 , Proteasas 3C de Coronavirus , Farmacorresistencia Viral , Lactamas , Leucina , Nitrilos , Prolina , Ritonavir , SARS-CoV-2 , Inhibidores de Proteasa Viral , Proteasas 3C de Coronavirus/antagonistas & inhibidores , Proteasas 3C de Coronavirus/genética , Combinación de Medicamentos , Farmacorresistencia Viral/genética , Humanos , Lactamas/farmacología , Lactamas/uso terapéutico , Leucina/farmacología , Leucina/uso terapéutico , Mutación , Nitrilos/farmacología , Nitrilos/uso terapéutico , Prolina/farmacología , Prolina/uso terapéutico , Ritonavir/farmacología , Ritonavir/uso terapéutico , SARS-CoV-2/efectos de los fármacos , SARS-CoV-2/genética , Inhibidores de Proteasa Viral/farmacología , Inhibidores de Proteasa Viral/uso terapéuticoAsunto(s)
Tratamiento Farmacológico de COVID-19 , Prueba de COVID-19 , COVID-19 , Inhibidores de Proteasa Viral , Antivirales/efectos adversos , Antivirales/uso terapéutico , COVID-19/complicaciones , COVID-19/diagnóstico , Combinación de Medicamentos , Humanos , Lactamas/efectos adversos , Lactamas/uso terapéutico , Leucina/efectos adversos , Leucina/uso terapéutico , Nitrilos/efectos adversos , Nitrilos/uso terapéutico , Prolina/efectos adversos , Prolina/uso terapéutico , Recurrencia , Ritonavir/efectos adversos , Ritonavir/uso terapéutico , Inhibidores de Proteasa Viral/efectos adversos , Inhibidores de Proteasa Viral/uso terapéuticoRESUMEN
The 2019 corona virus disease (COVID-19) has caused a global chaos, where a novel Omicron variant has challenged the healthcare system, followed by which it has been referred to as a variant of concern (VOC) by the World Health Organization (WHO), owing to its alarming transmission and infectivity rate. The large number of mutations in the receptor binding domain (RBD) of the spike protein is responsible for strengthening of the spike-angiotensin-converting enzyme 2 (ACE2) interaction, thereby explaining the elevated threat. This is supplemented by enhanced resistance of the variant towards pre-existing antibodies approved for the COVID-19 therapy. The manuscript brings into light failure of existing therapies to provide the desired effect, however simultaneously discussing the novel possibilities on the verge of establishing suitable treatment portfolio. The authors entail the risks associated with omicron resistance against antibodies and vaccine ineffectiveness on one side, and novel approaches and targets - kinase inhibitors, viral protease inhibitors, phytoconstituents, entry pathways - on the other. The manuscript aims to provide a holistic picture about the Omicron variant, by providing comprehensive discussions related to multiple aspects of the mutated spike variant, which might aid the global researchers and healthcare experts in finding an optimised solution to this pandemic.
Asunto(s)
COVID-19/fisiopatología , SARS-CoV-2/genética , SARS-CoV-2/metabolismo , Enzima Convertidora de Angiotensina 2/metabolismo , Animales , COVID-19/inmunología , Vacunas contra la COVID-19/inmunología , Catepsinas/metabolismo , Receptores ErbB/antagonistas & inhibidores , Humanos , Esquemas de Inmunización , Inmunización Secundaria , Fitoterapia/métodos , Plantas Medicinales , Unión Proteica/fisiología , Dominios y Motivos de Interacción de Proteínas/fisiología , Elementos Estructurales de las Proteínas/fisiología , Glicoproteína de la Espiga del Coronavirus/metabolismo , Inhibidores de Proteasa Viral/farmacología , Inhibidores de Proteasa Viral/uso terapéuticoAsunto(s)
Tratamiento Farmacológico de COVID-19 , Inhibidores del Citocromo P-450 CYP3A/uso terapéutico , Lactamas/uso terapéutico , Leucina/uso terapéutico , Nitrilos/uso terapéutico , Prolina/uso terapéutico , Ritonavir/uso terapéutico , Inhibidores de Proteasa Viral/uso terapéutico , Administración Oral , Combinación de Medicamentos , Interacciones Farmacológicas , Humanos , SARS-CoV-2RESUMEN
BACKGROUND: Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan-human-coronavirus activity in vitro. METHODS: We conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days. Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTS: A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group). In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths. Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%). All 13 deaths occurred in the placebo group. The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms. The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%). Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONS: Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns. (Supported by Pfizer; ClinicalTrials.gov number, NCT04960202.).
Asunto(s)
Antivirales , Tratamiento Farmacológico de COVID-19 , Lactamas , Leucina , Nitrilos , Prolina , Ritonavir , Administración Oral , Adulto , Antivirales/administración & dosificación , Antivirales/efectos adversos , Antivirales/uso terapéutico , Progresión de la Enfermedad , Método Doble Ciego , Hospitalización , Humanos , Lactamas/administración & dosificación , Lactamas/efectos adversos , Lactamas/uso terapéutico , Leucina/administración & dosificación , Leucina/efectos adversos , Leucina/uso terapéutico , Nitrilos/administración & dosificación , Nitrilos/efectos adversos , Nitrilos/uso terapéutico , Prolina/administración & dosificación , Prolina/efectos adversos , Prolina/uso terapéutico , Ritonavir/administración & dosificación , Ritonavir/efectos adversos , Ritonavir/uso terapéutico , SARS-CoV-2 , Resultado del Tratamiento , Vacunación , Carga Viral/efectos de los fármacos , Inhibidores de Proteasa Viral/administración & dosificación , Inhibidores de Proteasa Viral/efectos adversos , Inhibidores de Proteasa Viral/uso terapéuticoAsunto(s)
Tratamiento Farmacológico de COVID-19 , Vacunas contra la COVID-19/inmunología , Lactamas/uso terapéutico , Leucina/uso terapéutico , Nitrilos/uso terapéutico , Prolina/uso terapéutico , Eficacia de las Vacunas , Inhibidores de Proteasa Viral/uso terapéutico , Antivirales/uso terapéutico , COVID-19/inmunología , Combinación de Medicamentos , Interacciones Farmacológicas , Femenino , Humanos , Inmunidad Activa , Inmunogenicidad Vacunal , Masculino , Proyectos de Investigación , Ritonavir/uso terapéuticoAsunto(s)
Tratamiento Farmacológico de COVID-19 , Lactamas/uso terapéutico , Leucina/uso terapéutico , Nitrilos/uso terapéutico , Prolina/uso terapéutico , Ritonavir/efectos adversos , Ritonavir/uso terapéutico , Inhibidores de Proteasa Viral , Interacciones Farmacológicas , Quimioterapia Combinada , Humanos , Ritonavir/farmacocinética , Ritonavir/farmacología , Inhibidores de Proteasa Viral/efectos adversos , Inhibidores de Proteasa Viral/farmacocinética , Inhibidores de Proteasa Viral/uso terapéuticoRESUMEN
The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants.
Asunto(s)
Tratamiento Farmacológico de COVID-19 , Lactamas/farmacología , Lactamas/uso terapéutico , Leucina/farmacología , Leucina/uso terapéutico , Nitrilos/farmacología , Nitrilos/uso terapéutico , Prolina/farmacología , Prolina/uso terapéutico , SARS-CoV-2/efectos de los fármacos , Inhibidores de Proteasa Viral/farmacología , Inhibidores de Proteasa Viral/uso terapéutico , Administración Oral , Animales , COVID-19/virología , Ensayos Clínicos Fase I como Asunto , Coronavirus/efectos de los fármacos , Modelos Animales de Enfermedad , Quimioterapia Combinada , Humanos , Lactamas/administración & dosificación , Lactamas/farmacocinética , Leucina/administración & dosificación , Leucina/farmacocinética , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana , Nitrilos/administración & dosificación , Nitrilos/farmacocinética , Prolina/administración & dosificación , Prolina/farmacocinética , Ensayos Clínicos Controlados Aleatorios como Asunto , Ritonavir/administración & dosificación , Ritonavir/uso terapéutico , SARS-CoV-2/fisiología , Inhibidores de Proteasa Viral/administración & dosificación , Inhibidores de Proteasa Viral/farmacocinética , Replicación Viral/efectos de los fármacosRESUMEN
Coronavirus protease nsp5 (Mpro, 3CLpro) remains a primary target for coronavirus therapeutics due to its indispensable and conserved role in the proteolytic processing of the viral replicase polyproteins. In this review, we discuss the diversity of known coronaviruses, the role of nsp5 in coronavirus biology, and the structure and function of this protease across the diversity of known coronaviruses, and evaluate past and present efforts to develop inhibitors to the nsp5 protease with a particular emphasis on new and mostly unexplored potential targets of inhibition. With the recent emergence of pandemic SARS-CoV-2, this review provides novel and potentially innovative strategies and directions to develop effective therapeutics against the coronavirus protease nsp5.
Asunto(s)
Antivirales/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Proteasas 3C de Coronavirus/antagonistas & inhibidores , Proteasas 3C de Coronavirus/química , SARS-CoV-2/enzimología , Proteínas no Estructurales Virales/antagonistas & inhibidores , Inhibidores de Proteasa Viral/uso terapéutico , Secuencia de Aminoácidos , COVID-19/virología , Coronavirus/enzimología , Coronavirus/metabolismo , Proteasas 3C de Coronavirus/genética , Proteasas 3C de Coronavirus/metabolismo , Humanos , Filogenia , SARS-CoV-2/metabolismo , Proteínas no Estructurales Virales/metabolismoRESUMEN
We aimed to describe liver injury and identify the risk factors of liver injury in coronavirus disease (COVID-19) patients without chronic liver diseases (CLD). The clinical data of 228 confirmed COVID-19 patients without CLD were retrospectively collected from ten hospitals in Jiangsu, China. Sixty-seven (29.4%) of 228 patients without CLD showed abnormal liver function on admission, including increased alanine aminotransferase (ALT) (25 [11.0%]) U/L, aspartate aminotransferase (AST) 30 [13.2%]) U/L, gamma-glutamyl transferase (GGT) 28 [12.4%]) U/L, total bilirubin (Tbil) 16 [7.0%] µmol/L, and alkaline phosphatase (ALP) 10 [4.5%]) U/L. During hospitalization, 129 (56.3%) of 228 patients showed abnormal liver function, including elevated ALT (84 [36.8%]), AST (58 [25.4%]), GGT (67 [29.5%]), and Tbil (59 [25.9%]). Age over 50 years (odds ratio [OR], 2.086; 95% confidence interval [CI], 1.030-4.225; p = .041), male sex (OR, 2.737; 95% CI, 1.418-5.284; p = .003), and lopinavir-ritonavir (OR, 2.504; 95% CI, 1.187-5.283; p = .016) were associated with higher risk of liver function abnormality, while the atomized inhalation of interferon α-2b (OR, 0.256; 95% CI 0.126-0.520; p < .001) was associated with reduced risk of liver function abnormality during hospitalization. Mild to moderate liver injury was common in COVID-19 patients in Jiangsu, China. Age over 50 years, male sex, and lopinavir-ritonavir were the independent risk factors of liver impairment in COVID-19 patients during hospitalization.
Asunto(s)
COVID-19/patología , Hepatopatías/virología , Adulto , COVID-19/epidemiología , COVID-19/virología , China/epidemiología , Femenino , Hospitalización , Humanos , Hepatopatías/epidemiología , Hepatopatías/patología , Pruebas de Función Hepática , Lopinavir/uso terapéutico , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Ritonavir , SARS-CoV-2/aislamiento & purificación , Inhibidores de Proteasa Viral/efectos adversos , Inhibidores de Proteasa Viral/uso terapéutico , Tratamiento Farmacológico de COVID-19Asunto(s)
Terapia Antirretroviral Altamente Activa , Tratamiento Farmacológico de COVID-19 , Inhibidores de Proteasa de Coronavirus/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Inhibidores de la Transcriptasa Inversa/uso terapéutico , SARS-CoV-2/metabolismo , Proteasas 3C de Coronavirus/antagonistas & inhibidores , Proteasas 3C de Coronavirus/metabolismo , ARN Polimerasa Dependiente de ARN de Coronavirus/antagonistas & inhibidores , ARN Polimerasa Dependiente de ARN de Coronavirus/metabolismo , Reposicionamiento de Medicamentos , Humanos , Inhibidores de Integrasa/uso terapéutico , Índice de Severidad de la Enfermedad , Inhibidores de Proteasa Viral/uso terapéuticoRESUMEN
Selenium is a trace element essential to human health largely because of its incorporation into selenoproteins that have a wide range of protective functions. Selenium has an ongoing history of reducing the incidence and severity of various viral infections; for example, a German study found selenium status to be significantly higher in serum samples from surviving than non-surviving COVID-19 patients. Furthermore, a significant, positive, linear association was found between the cure rate of Chinese patients with COVID-19 and regional selenium status. Moreover, the cure rate continued to rise beyond the selenium intake required to optimise selenoproteins, suggesting that selenoproteins are probably not the whole story. Nonetheless, the significantly reduced expression of a number of selenoproteins, including those involved in controlling ER stress, along with increased expression of IL-6 in SARS-CoV-2 infected cells in culture suggests a potential link between reduced selenoprotein expression and COVID-19-associated inflammation. In this comprehensive review, we describe the history of selenium in viral infections and then go on to assess the potential benefits of adequate and even supra-nutritional selenium status. We discuss the indispensable function of the selenoproteins in coordinating a successful immune response and follow by reviewing cytokine excess, a key mediator of morbidity and mortality in COVID-19, and its relationship to selenium status. We comment on the fact that the synthetic redox-active selenium compound, ebselen, has been found experimentally to be a strong inhibitor of the main SARS-CoV-2 protease that enables viral maturation within the host. That finding suggests that redox-active selenium species formed at high selenium intake might hypothetically inhibit SARS-CoV-2 proteases. We consider the tactics that SARS-CoV-2 could employ to evade an adequate host response by interfering with the human selenoprotein system. Recognition of the myriad mechanisms by which selenium might potentially benefit COVID-19 patients provides a rationale for randomised, controlled trials of selenium supplementation in SARS-CoV-2 infection.